Le Lézard
Classified in: Health, Business
Subjects: PDT, LIC

New Rapid Cardiac MR Imaging Helps Detect and Manage Patient Heart Health During and After Cancer Treatments


HOUSTON, Aug. 5, 2020 /PRNewswire/ -- United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, along with Myocardial Solutions, a medical technology company working to transform the cardiac and cancer care continuum, announced today FDA premarket clearance to market MyoStrain® software on United Imaging's uMR scanners. MyoStrain® is a rapid MRI-based heart function test that quantifies the effects of disease, drugs, and ischemia across 48 heart segments in under 10 minutes. It can be used to direct curative cardio-protective therapy to protect the heart without interfering with the cancer treatment during or after cancer therapy.

"While more and more cancers are considered curable today, many available therapies can be toxic to the heart, leading to dysfunction and eventually heart failure," said Jeffrey M. Bundy, Ph.D., CEO, United Imaging Healthcare Solutions in the U.S. "We believe this new test is a game-changer, providing information that will help oncologists everywhere reduce the risk of their patients developing heart disease due to therapy. Our 1.5T uMR scanners for MyoStrain are currently ready to ship from our Houston-based factory to customers." United Imaging announced the opening of its factory in late July, just eight weeks after launching uMR OMEGAtm, a world's-first 75-cm ultra-wide-bore 3.0T MR system; in short order, both those events and this new partnership have even further cemented its place as a significant U.S. imaging provider.

Heart failure is a common condition and can be often fatal when detected too late. MyoStrain provides a fast, non-invasive way to help doctors detect heart dysfunction before irreversible damage or even heart failure occurs. MyoStrain measures segmental strain to show cardiac effects due to cancer treatment, chronic diseases, and ischemia and allows physicians to monitor heart health over time.

"MyoStrain is the first diagnostic tool that enables physicians to detect the effects of cardiotoxicity early and manage cardio-protective therapy for optimal individualized care," stated Peter Gaccione, President of Myocardial Solutions. "Our partnership with United Imaging makes a fast, easy, and patient-centric test available for providers and their cancer patients. This announcement marks the next major milestone for MyoStrain following the release of dedicated HCPCS codes from CMS which went into effect on July 1, 2020. Providers can now have access to MyoStrain through United Imaging and can support a cardiac oncology practice with designated Medicare reimbursement."

"With this joint solution from Myocardial Solutions and United Imaging, oncologists and cardiologists will be able to monitor patient heart health before, during, and after cancer treatment," said Abram Voorhees, Ph.D., Vice President of MR at United Imaging. "Together, United Imaging and Myocardial Solutions will deliver the diagnostic testing using MyoStrain software on a dedicated MR scanner for both cancer centers and cardiologists. The fast, MR-based technique is highly automated to deliver reproducible results."

United Imaging is the preferred provider for MyoStrain, and the two companies have joined together to bring this dedicated solution to cancer centers and hospitals. The FDA's 510(k) premarket clearance of the technology for United Imaging MRI machines marks the availability of this technology for the U.S. market.

ABOUT MYOCARDIAL SOLUTIONS, INC.

Myocardial Solutions, Inc. (MSI) is a medical technology company working to transform the cardiac and cancer care continuum. Leveraging more than 400 publications in clinical research and development, MSI's proprietary technology, MyoStrain®, is a 10-minute, non-invasive heart function test providing physicians with sensitive diagnostic markers to support the early assessment and individualized treatment of heart dysfunction. MyoStrain has received FDA-510(k) pre-market clearance, CE-mark certification, and is commercially available in the United States and Europe. To learn more about MyoStrain®, visit myocardialsolutions.com or connect with us on LinkedIn and Twitter @myocardialsoln.

ABOUT UNITED IMAGING

At United Imaging, we develop and produce advanced medical products, digital healthcare solutions, and intelligent solutions that cover the entire process of imaging diagnosis and treatment. Founded in 2011, our company has subsidiaries and R&D centers across the world. Our North American headquarters in Houston includes our corporate offices, factory, product showroom, service training center, and service parts distribution center. With a cutting-edge digital portfolio and a mission of broader access to healthcare for all, we help drive industry progress and bold change.

To learn more, visit united-imaging.com or follow us on LinkedIn and Twitter @UnitedImagingHC.

SOURCE United Imaging Healthcare Co., Ltd.


These press releases may also interest you

at 04:05
Halper Sadeh LLP, a global investor rights law firm, is investigating: Akcea Therapeutics, Inc.  concerning potential violations...

at 03:01
Cancer Genetics, Inc.  concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its merger with StemoniX, Inc. Under the merger agreement, Cancer Genetics will acquire all of the outstanding...

at 02:00
Qi Card today announced that it has seen increases in two important metrics for the company: in-app usage among current card holders and issuance of new Master Qi Cards. By the close of 2020, Qi Card will have five times more Master Cards in...

25 sep 2020
This press release provides shareholders of Cohen & Steers Infrastructure Fund, Inc. (the "Fund") with information regarding the sources of the distribution to be paid on September 30, 2020 and cumulative distributions paid fiscal year-to-date. In...

25 sep 2020
If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq.WeissLaw LLP1500 Broadway, 16th FloorNew...

25 sep 2020
Montage Resources Corporation WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Montage Resources Corporation in connection with the proposed acquisition of the company by...



News published on 5 august 2020 at 12:00 and distributed by: